The clinically relevant pharmacogenomic changes in acute myelogenous leukemia

Pharmacogenomics

Volumn 13, Issue 11, 2012, Pages 1257-1269

  Emadi, Ashkan ^a   Karp, Judith E ^b  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

acute myelogenous leukemia; AML; anthracycline; APTX; ara C; cytarabine; farnesyltransferase; pharmacogenomic; RASGRP1

Indexed keywords

3 AMINOPICOLINALDEHYDE THIOSEMICARBAZONE; 5' NUCLEOTIDASE; ABC TRANSPORTER; ANTHRACYCLINE; CARUBICIN; CYCLOSPORIN A; CYTARABINE; CYTIDINE DEAMINASE; CYTIDINE TRIPHOSPHATE SYNTHASE; DAUNORUBICIN; DEOXYCYTIDINE KINASE; DOXORUBICIN; EPIRUBICIN; EQUILIBRATIVE NUCLEOSIDE TRANSPORTER 1; ETOPOSIDE; FLUDARABINE; GEMCITABINE; GLUTATHIONE TRANSFERASE; HYDROXYUREA; IDARUBICIN; MULTIDRUG RESISTANCE PROTEIN 1; PROTEIN FARNESYLTRANSFERASE INHIBITOR; RIBONUCLEOTIDE REDUCTASE; TIPIFARNIB;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LEUKEMIA; ADULT; APTX GENE; ARTICLE; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CHROMOSOME 6; DISEASE FREE SURVIVAL; DRUG BLOOD LEVEL; DRUG MECHANISM; DRUG METABOLISM; DRUG RESPONSE; DRUG STRUCTURE; EVENT FREE SURVIVAL; GENE; GENE EXPRESSION; GENETIC VARIABILITY; GENOTYPE; GERIATRIC PATIENT; HUMAN; INDUCTION CHEMOTHERAPY; MULTIPLE CYCLE TREATMENT; MYELOPROLIFERATIVE NEOPLASM; OVERALL SURVIVAL; PERSONALIZED MEDICINE; PHARMACOGENOMICS; PROGRESSION FREE SURVIVAL; PROTEIN DEPHOSPHORYLATION; RASGRP1 GENE; RECURRENCE FREE SURVIVAL; SINGLE NUCLEOTIDE POLYMORPHISM;

ANTHRACYCLINES; CYTARABINE; DNA-BINDING PROTEINS; FARNESYLTRANSTRANSFERASE; GLUTATHIONE TRANSFERASE; GUANINE NUCLEOTIDE EXCHANGE FACTORS; HUMANS; INDIVIDUALIZED MEDICINE; LEUKEMIA, MYELOID, ACUTE; META-ANALYSIS AS TOPIC; NUCLEAR PROTEINS; PHARMACOGENETICS;

ARA;

EID: 84865445837     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.12.102     Document Type: Article

References (125)

1. Levis M, Murphy KM, Pham R et al. Internal tandem duplications of the FLT3 gene are present in leukemia stem cells. Blood 106(2), 673-680 (2005). (Pubitemid 40981265)
2. Levis M. FLT3/ITD AML and the law of unintended consequences. Blood 117(26), 6987-6990 (2011).
3. Boissel N, Renneville A, Biggio V et al. Prevalence, clinical profile, and prognosis of NPM mutations in AML with normal karyotype. Blood 106(10), 3618-3620 (2005). (Pubitemid 41609201)
4. Dufour A, Schneider F, Hoster E et al. Monoallelic CEBPA mutations in normal karyotype acute myeloid leukemia: independent favorable prognostic factor within NPM1 mutated patients. Ann. Hematol. 91(7), 1051-1063 (2012).
5. Hou HA, Kuo YY, Liu CY et al. DNMT3A mutations in acute myeloid leukemia: stability during disease evolution and clinical implications. Blood 119(2), 559-568 (2012).
6. Marcucci G, Maharry K, Wu YZ et al. IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. J. Clin. Oncol. 28(14), 2348-2355 (2010).
7. Paschka P, Schlenk RF, Gaidzik VI et al. IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal tandem duplication. J. Clin. Oncol. 28(22), 3636-3643 (2010).
8. Park SH, Chi HS, Min SK, Park BG, Jang S, Park CJ. Prognostic impact of c-KIT mutations in core binding factor acute myeloid leukemia. Leuk. Res. 35(10), 1376-1383 (2011).
9. Paschka P, Marcucci G, Ruppert AS et al. Wilms' tumor 1 gene mutations independently predict poor outcome in adults with cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. J. Clin. Oncol. 26(28), 4595-4602 (2008).
10. Dohner H, Estey EH, Amadori S et al. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood 115(3), 453-474 (2010).
11. Sanz MA, Grimwade D, Tallman MS et al. Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood 113(9), 1875-1891 (2009).
12. Estey EH. Acute myeloid leukemia: 2012 update on diagnosis, risk stratification, and management. Am. J. Hematol. 87(1), 89-99 (2012).
13. Cohen SS. Introduction to the biochemistry of d-arabinosyl nucleosides. Prog. Nucleic Acid Res. Mol. Biol. 5, 1-88 (1966).
14. Chu MY, Fischer GA. A proposed mechanism of action of 1-b-d-arabinofuranosyl-cytosine as an inhibitor of the growth of leukemic cells. Biochem. Pharmacol. 11, 423-430 (1962).
15. Borun TW, Scharff MD, Robbins E. Rapidly labeled, polyribosome-associated RNA having the properties of histone messenger. Proc. Natl Acad. Sci. USA 58(5), 1977-1983 (1967).
16. Creasey WA, Deconti RC, Kaplan SR. Biochemical studies with 1-b-d-arabinofuranosylcytosine in human leukemic leukocytes and normal bone marrow cells. Cancer Res. 28(6), 1074-1081 (1968).
17. Capizzi RL, Yang JL, Cheng E et al. Alteration of the pharmacokinetics of high-dose ara-C by its metabolite, high ara-U in patients with acute leukemia. J. Clin. Oncol. 1(12), 763-771 (1983). (Pubitemid 14167250)
18. Wiley JS, Taupin J, Jamieson GP, Snook M, Sawyer WH, Finch LR. Cytosine arabinoside transport and metabolism in acute leukemias and T cell lymphoblastic lymphoma. J. Clin. Invest. 75(2), 632-642 (1985). (Pubitemid 15142074)
19. Sundaram M, Yao SY, Ingram JC et al. Topology of a human equilibrative, nitrobenzylthioinosine (NBMPR)-sensitive nucleoside transporter (hENT1) implicated in the cellular uptake of adenosine and anti-cancer drugs. J. Biol. Chem. 276(48), 45270-45275 (2001).
20. Galmarini CM, Thomas X, Calvo F et al. Potential mechanisms of resistance to cytarabine in AML patients. Leuk. Res. 26(7), 621-629 (2002). (Pubitemid 34465699)
21. Gati WP, Paterson AR, Larratt LM, Turner AR, Belch AR. Sensitivity of acute leukemia cells to cytarabine is a correlate of cellular es nucleoside transporter site content measured by flow cytometry with SAENTA-fluorescein. Blood 90(1), 346-353 (1997). (Pubitemid 27276580)
22. Montero TD, Racordon D, Bravo L, Owen GI, Bronfman ML, Leisewitz AV. PPARa and PPARg regulate the nucleoside transporter hENT1. Biochem. Biophys. Res. Commun. 419(2), 405-411 (2012).
23. Eltzschig HK, Abdulla P, Hoffman E et al. HIF-1-dependent repression of equilibrative nucleoside transporter (ENT) in hypoxia. J. Exp. Med. 202(11), 1493-1505 (2005). (Pubitemid 41746596)
24. Kakihara T, Fukuda T, Tanaka A et al. Expression of deoxycytidine kinase (dCK) gene in leukemic cells in childhood: decreased expression of dCK gene in relapsed leukemia. Leuk. Lymphoma 31(3-4), 405-409 (1998). (Pubitemid 29033962)
25. Van Der Wilt CL, Kroep JR, Loves WJ et al. Expression of deoxycytidine kinase in leukaemic cells compared with solid tumour cell lines, liver metastases and normal liver. Eur. J. Cancer 39(5), 691-697 (2003). (Pubitemid 36287383)
26. Shi JY, Shi ZZ, Zhang SJ et al. Association between single nucleotide polymorphisms in deoxycytidine kinase and treatment response among acute myeloid leukaemia patients. Pharmacogenetics 14(11), 759-768 (2004).
27. Mahlknecht U, Dransfeld CL, Bulut N et al. SNP analyses in cytarabine metabolizing enzymes in AML patients and their impact on treatment response and patient survival: identification of CDA SNP C-451T as an independent prognostic parameter for survival. Leukemia 23(10), 1929-1932 (2009).
28. Lamba JK. Genetic factors influencing cytarabine therapy. Pharmacogenomics 10(10), 1657-1674 (2009).
29. Verschuur AC, Van Gennip AH, Leen R, Voute PA, Van Kuilenburg AB. Cyclopentenyl cytosine increases the phosphorylation and incorporation into DNA of arabinofu-ranosyl cytosine in a myeloid leukemic cell-line. Adv. Exp. Med. Biol. 486, 311-317 (2000). (Pubitemid 32179318)
30. Tattersall MH, Ganeshaguru K, Hoffbrand AV. Mechanisms of resistance of human acute leukaemia cells to cytosine arabinoside. Br. J. Haematol. 27(1), 39-46 (1974).
31. Meuth M. The molecular basis of mutations induced by deoxyribonucleoside triphosphate pool imbalances in mammalian cells. Exp. Cell. Res. 181(2), 305-316 (1989). (Pubitemid 19096399)
32. Chiba P, Tihan T, Szekeres T et al. Concordant changes of pyrimidine metabolism in blasts of two cases of acute myeloid leukemia after repeated treatment with ara-C in vivo. Leukemia 4(11), 761-765 (1990). (Pubitemid 20385401)
33. Shao J, Zhou B, Chu B, Yen Y. Ribonucleotide reductase inhibitors and future drug design. Curr. Cancer Drug Targets 6(5), 409-431 (2006). (Pubitemid 44033390)
34. Sigmond J, Kamphuis JA, Laan AC, Hoebe EK, Bergman AM, Peters GJ. The synergistic interaction of gemcitabine and cytosine arabinoside with the ribonucleotide reductase inhibitor triapine is schedule dependent. Biochem. Pharmacol. 73(10), 1548-1557 (2007). (Pubitemid 46527545)
35. Karp JE, Giles FJ, Gojo I et al. A Phase I study of the novel ribonucleotide reductase inhibitor 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, Triapine) in combination with the nucleoside analog fludarabine for patients with refractory acute leukemias and aggressive myeloproliferative disorders. Leuk. Res. 32(1), 71-77 (2008). (Pubitemid 350100849)
36. Dumontet C, Bauchu EC, Fabianowska K et al. Common resistance mechanisms to nucleoside analogues in variants of the human erythroleukemic line K562. Adv. Exp. Med. Biol. 457, 571-577 (1999). (Pubitemid 129735354)
37. Hunsucker SA, Mitchell BS, Spychala J. The 5́-nucleotidases as regulators of nucleotide and drug metabolism. Pharmacol. Ther. 107(1), 1-30 (2005). (Pubitemid 40800406)
38. Galmarini CM, Cros E, Thomas X, Jordheim L, Dumontet C. The prognostic value of cN-II and cN-III enzymes in adult acute myeloid leukemia. Haematologica 90(12), 1699-1701 (2005). (Pubitemid 41814998)
39. Mitra AK, Crews KR, Pounds S et al. Genetic variants in cytosolic 5́-nucleotidase II are associated with its expression and cytarabine sensitivity in HapMap cell lines and in patients with acute myeloid leukemia. J. Pharmacol. Exp. Ther. 339(1), 9-23 (2011).
40. Jahns-Streubel G, Reuter C, Auf Der Landwehr U et al. Activity of thymidine kinase and of polymerase a as well as activity and gene expression of deoxycytidine deaminase in leukemic blasts are correlated with clinical response in the setting of granulocyte-macrophage colony-stimulating factor-based priming before and during TAD-9 induction therapy in acute myeloid leukemia. Blood 90(5), 1968-1976 (1997). (Pubitemid 27377308)
41. Schroder JK, Kirch C, Seeber S, Schutte J. Structural and functional analysis of the cytidine deaminase gene in patients with acute myeloid leukaemia. Br. J. Haematol. 103(4), 1096-1103 (1998). (Pubitemid 29012650)
42. Gilbert JA, Salavaggione OE, Ji Y et al. Gemcitabine pharmacogenomics: cytidine deaminase and deoxycytidylate deaminase gene resequencing and functional genomics. Clin. Cancer Res. 12(6), 1794-1803 (2006).
43. Yue L, Saikawa Y, Ota K et al. A functional single-nucleotide polymorphism in the human cytidine deaminase gene contributing to ara-C sensitivity. Pharmacogenetics 13(1), 29-38 (2003). (Pubitemid 36135684)
44. Fitzgerald SM, Goyal RK, Osborne WR, Roy JD, Wilson JW, Ferrell RE. Identification of functional single nucleotide polymorphism haplotypes in the cytidine deaminase promoter. Hum. Genet. 119(3), 276-283 (2006).
45. Bhatla D, Gerbing RB, Alonzo TA et al. Cytidine deaminase genotype and toxicity of cytosine arabinoside therapy in children with acute myeloid leukemia. Br. J. Haematol. 144(3), 388-394 (2009).
46. Ciccolini J, Dahan L, Andre N et al. Cytidine deaminase residual activity in serum is a predictive marker of early severe toxicities in adults after gemcitabine-based chemotherapies. J. Clin. Oncol. 28(1), 160-165 (2010).
47. Giovannetti E, Tibaldi C, Falcone A, Danesi R, Peters GJ. Impact of cytidine deaminase polymorphisms on toxicity after gemcitabine: the question is still ongoing. J. Clin. Oncol. 28(14), E221-E225 (2010).
48. Banklau C, Jindadamrongwech S, Sawangpanich R et al. Effect of genetic alterations of cytarabine-metabolizing enzymes in childhood acute lymphoblastic leukemia. Hematol. Oncol. Stem Cell. Ther. 3(3), 103-108 (2010).
49. Capizzi RL, White JC, Powell BL, Perrino F. Effect of dose on the pharmacokinetic and pharmacodynamic effects of cytarabine. Semin. Hematol. 28(3 Suppl. 4), S54-S69 (1991).
50. Fridland A, Verhoef V. Mechanism for ara-CTP catabolism in human leukemic cells and effect of deaminase inhibitors on this process. Semin. Oncol. 14(2 Suppl. 1), S262-S268 (1987).
51. Weiss RB. The anthracyclines: will we ever find a better doxorubicin? Semin. Oncol. 19(6), 670-686 (1992). (Pubitemid 23004844)
52. Momparler RL, Karon M, Siegel SE, Avila F. Effect of adriamycin on DNA, RNA, and protein synthesis in cell-free systems and intact cells. Cancer Res. 36(8), 2891-2895 (1976).
53. Frederick CA, Williams LD, Ughetto G et al. Structural comparison of anticancer drug-DNA complexes: adriamycin and daunomycin. Biochemistry 29(10), 2538-2549 (1990). (Pubitemid 20100850)
54. Pigram WJ, Fuller W, Hamilton LD. Stereochemistry of intercalation: interaction of daunomycin with DNA. Nat. New Biol. 235(53), 17-19 (1972).
55. Lown JW, Chen HH, Plambeck JA, Acton EM. Diminished superoxide anion generation by reduced 5-iminodaunorubicin relative to daunorubicin and the relationship to cardiotoxicity of the anthracycline antitumor agents. Biochem. Pharmacol. 28(17), 2563-2568 (1979). (Pubitemid 10229269)
56. Dassa E, Bouige P. The ABC of ABCS: a phylogenetic and functional classification of ABC systems in living organisms. Res. Microbiol. 152(3-4), 211-229 (2001). (Pubitemid 32436481)
57. Dean M, Allikmets R. Complete characterization of the human ABC gene family. J. Bioenerg. Biomembr. 33(6), 475-479 (2001). (Pubitemid 34052573)
58. Dean M, Rzhetsky A, Allikmets R. The human ATP-binding cassette (ABC) transporter superfamily. Genome Res. 11(7), 1156-1166 (2001). (Pubitemid 32677289)
59. Gottesman MM, Ling V. The molecular basis of multidrug resistance in cancer: the early years of P-glycoprotein research. FEBS Lett. 580(4), 998-1009 (2006). (Pubitemid 43185280)
60. Szakacs G, Paterson JK, Ludwig JA, Booth-Genthe C, Gottesman MM. Targeting multidrug resistance in cancer. Nat. Rev. Drug Discov. 5(3), 219-234 (2006). (Pubitemid 43336035)
61. Litman T, Druley TE, Stein WD, Bates SE. From MDR to MXR: new understanding of multidrug resistance systems, their properties and clinical significance. Cell Mol. Life Sci. 58(7), 931-959 (2001). (Pubitemid 32652819)
62. Sharom FJ. ABC multidrug transporters: structure, function and role in chemoresistance. Pharmacogenomics 9(1), 105-127 (2008). (Pubitemid 351560534)
63. Leith CP, Kopecky KJ, Chen IM et al. Frequency and clinical significance of the expression of the multidrug resistance proteins MDR1/P-glycoprotein, MRP1, and LRP in acute myeloid leukemia: a Southwest Oncology Group Study. Blood 94(3), 1086-1099 (1999). (Pubitemid 29361842)
64. Seedhouse CH, Grundy M, White P et al. Sequential influences of leukemia-specific and genetic factors on p-glycoprotein expression in blasts from 817 patients entered into the National Cancer Research Network acute myeloid leukemia 14 and 15 trials. Clin. Cancer Res. 13(23), 7059-7066 (2007). (Pubitemid 350276888)
65. List AF, Kopecky KJ, Willman CL et al. Benefit of cyclosporine modulation of drug resistance in patients with poor-risk acute myeloid leukemia: a Southwest Oncology Group study. Blood 98(12), 3212-3220 (2001).
66. Kolitz JE, George SL, Dodge RK et al. Dose escalation studies of cytarabine, daunorubicin, and etoposide with and without multidrug resistance modulation with PSC-833 in untreated adults with acute myeloid leukemia younger than 60 years: final induction results of Cancer and Leukemia Group B Study 9621. J. Clin. Oncol. 22(21), 4290-4301 (2004). (Pubitemid 41185150)
67. Baer MR, George SL, Dodge RK et al. Phase 3 study of the multidrug resistance modulator PSC-833 in previously untreated patients 60 years of age and older with acute myeloid leukemia: Cancer and Leukemia Group B Study 9720. Blood 100(4), 1224-1232 (2002). (Pubitemid 34864276)
68. Liu Yin JA, Wheatley K, Rees JK, Burnett AK. Comparison of 'sequential' versus 'standard' chemotherapy as re-induction treatment, with or without cyclosporine, in refractory/relapsed acute myeloid leukaemia (AML): results of the UK Medical Research Council AML-R trial. Br. J. Haematol. 113(3), 713-726 (2001). (Pubitemid 32524396)
69. Van Der Holt B, Lowenberg B, Burnett AK et al. The value of the MDR1 reversal agent PSC-833 in addition to daunorubicin and cytarabine in the treatment of elderly patients with previously untreated acute myeloid leukemia (AML), in relation to MDR1 status at diagnosis. Blood 106(8), 2646-2654 (2005). (Pubitemid 41510736)
70. Sonneveld P, Suciu S, Weijermans P et al. Cyclosporin A combined with vincristine, doxorubicin and dexamethasone (VAD) compared with VAD alone in patients with advanced refractory multiple myeloma: an EORTC-HOVON randomized Phase III study (06914). Br. J. Haematol. 115(4), 895-902 (2001). (Pubitemid 34044154)
71. Solary E, Drenou B, Campos L et al. Quinine as a multidrug resistance inhibitor: a Phase 3 multicentric randomized study in adult de novo acute myelogenous leukemia. Blood 102(4), 1202-1210 (2003). (Pubitemid 36988023)
72. Solary E, Witz B, Caillot D et al. Combination of quinine as a potential reversing agent with mitoxantrone and cytarabine for the treatment of acute leukemias: a randomized multicenter study. Blood 88(4), 1198-1205 (1996). (Pubitemid 26276794)
73. Raaijmakers MH, De Grouw EP, Van Der Reijden BA, De Witte TJ, Jansen JH, Raymakers RA. ABCB1 modulation does not circumvent drug extrusion from primitive leukemic progenitor cells and may preferentially target residual normal cells in acute myelogenous leukemia. Clin. Cancer Res. 12(11 Pt 1), 3452-3458 (2006).
74. Damiani D, Tiribelli M, Calistri E et al. The prognostic value of P-glycoprotein (ABCB) and breast cancer resistance protein (ABCG2) in adults with de novo acute myeloid leukemia with normal karyotype. Haematologica 91(6), 825-828 (2006). (Pubitemid 44014553)
75. Guo Y, Kock K, Ritter CA et al. Expression of ABCC-type nucleotide exporters in blasts of adult acute myeloid leukemia: relation to long-term survival. Clin. Cancer Res. 15(5), 1762-1769 (2009).
76. Doyle LA, Yang W, Abruzzo LV et al. A multidrug resistance transporter from human MCF-7 breast cancer cells. Proc. Natl Acad. Sci. USA 95(26), 15665-15670 (1998). (Pubitemid 29018757)
77. Ross DD, Yang W, Abruzzo LV et al. Atypical multidrug resistance: breast cancer resistance protein messenger RNA expression in mitoxantrone-selected cell lines. J. Natl Cancer Inst. 91(5), 429-433 (1999). (Pubitemid 29128278)
78. Lemos C, Jansen G, Peters GJ. Drug transporters: recent advances concerning BCRP and tyrosine kinase inhibitors. Br. J. Cancer 98(5), 857-862 (2008). (Pubitemid 351341599)
79. Ross DD, Karp JE, Chen TT, Doyle LA. Expression of breast cancer resistance protein in blast cells from patients with acute leukemia. Blood 96(1), 365-368 (2000). (Pubitemid 30456496)
80. Hampras SS, Sucheston L, Weiss J et al. Genetic polymorphisms of ATP-binding cassette (ABC) proteins, overall survival and drug toxicity in patients with acute myeloid leukemia. Int. J. Mol. Epidemiol. Genet. 1(3), 201-207 (2010).
81. Benderra Z, Faussat AM, Sayada L et al. MRP3, BCRP, and P-glycoprotein activities are prognostic factors in adult acute myeloid leukemia. Clin. Cancer Res. 11(21), 7764-7772 (2005). (Pubitemid 41611620)
82. Chapuy B, Koch R, Radunski U et al. Intracellular ABC transporter A3 confers multidrug resistance in leukemia cells by lysosomal drug sequestration. Leukemia 22(8), 1576-1586 (2008).
83. Sheehan D, Meade G, Foley VM, Dowd CA. Structure, function and evolution of glutathione transferases: implications for classification of non-mammalian members of an ancient enzyme superfamily. Biochem. J. 360(Pt 1), 1-16 (2001). (Pubitemid 33081943)
84. Douglas KT. Mechanism of action of glutathione-dependent enzymes. Adv. Enzymol. Relat. Areas Mol. Biol. 59, 103-167 (1987).
85. Tsunada S, Iwakiri R, Noda T et al. Chronic exposure to subtoxic levels of peroxidized lipids suppresses mucosal cell turnover in rat small intestine and reversal by glutathione. Dig. Dis. Sci. 48(1), 210-222 (2003). (Pubitemid 36232785)
86. Santella RM, Perera FP, Young TL et al. Polycyclic aromatic hydrocarbon-DNA and protein adducts in coal tar treated patients and controls and their relationship to glutathione S-transferase genotype. Mutat. Res. 334(2), 117-124 (1995).
87. Whyatt RM, Perera FP, Jedrychowski W, Santella RM, Garte S, Bell DA. Association between polycyclic aromatic hydrocarbon-DNA adduct levels in maternal and newborn white blood cells and glutathione S-transferase P1 and CYP1A1 polymorphisms. Cancer Epidemiol. Biomarkers Prev. 9(2), 207-212 (2000). (Pubitemid 30111945)
88. Weiserbs KF, Jacobson JS, Begg MD et al. A cross-sectional study of polycyclic aromatic hydrocarbon-DNA adducts and polymorphism of glutathione S-transferases among heavy smokers by race/ethnicity. Biomarkers 8(2), 142-155 (2003). (Pubitemid 36747950)
89. Obolenskaya MY, Teplyuk NM, Divi RL et al. Human placental glutathione S-transferase activity and polycyclic aromatic hydrocarbon DNA adducts as biomarkers for environmental oxidative stress in placentas from pregnant women living in radioactivity-and chemically-polluted regions. Toxicol. Lett. 196(2), 80-86 (2010).
90. Colvin OM, Friedman HS, Gamcsik MP, Fenselau C, Hilton J. Role of glutathione in cellular resistance to alkylating agents. Adv. Enzyme Regul. 33, 19-26 (1993). (Pubitemid 223051907)
91. Biroccio A, Benassi B, Fiorentino F, Zupi G. Glutathione depletion induced by c-Myc downregulation triggers apoptosis on treatment with alkylating agents. Neoplasia 6(3), 195-206 (2004). (Pubitemid 38657075)
92. Lutzky J, Astor MB, Taub RN et al. Role of glutathione and dependent enzymes in anthracycline-resistant HL60/AR cells. Cancer Res. 49(15), 4120-4125 (1989). (Pubitemid 19207246)
93. L'Ecuyer T, Allebban Z, Thomas R, Vander Heide R. Glutathione S-transferase overexpression protects against anthracycline-induced H9C2 cell death. Am. J. Physiol. Heart Circ. Physiol. 286(6), H2057-H2064 (2004). (Pubitemid 38685217)
94. Wilce MC, Parker MW. Structure and function of glutathione S-transferases. Biochim. Biophys. Acta 1205(1), 1-18 (1994).
95. Rebbeck TR. Molecular epidemiology of the human glutathione S-transferase genotypes GSTM1 and GSTT1 in cancer susceptibility. Cancer Epidemiol. Biomarkers Prev. 6(9), 733-743 (1997). (Pubitemid 27427630)
96. Basu T, Gale RE, Langabeer S, Linch DC. Glutathione S-transferase theta 1 (GSTT1) gene defect in myelodysplasia and acute myeloid leukaemia. Lancet 349(9063), 1450 (1997).
97. Rollinson S, Roddam P, Kane E et al. Polymorphic variation within the glutathione S-transferase genes and risk of adult acute leukaemia. Carcinogenesis 21(1), 43-47 (2000). (Pubitemid 30064142)
98. Crump C, Chen C, Appelbaum FR et al. Glutathione S-transferase q 1 gene deletion and risk of acute myeloid leukemia. Cancer Epidemiol. Biomarkers Prev. 9(5), 457-460 (2000). (Pubitemid 30313887)
99. Woo MH, Shuster JJ, Chen C et al. Glutathione S-transferase genotypes in children who develop treatment-related acute myeloid malignancies. Leukemia 14(2), 232-237 (2000). (Pubitemid 30095376)
100. Voso MT, D'alo F, Putzulu R et al. Negative prognostic value of glutathione S-transferase (GSTM1 and GSTT1) deletions in adult acute myeloid leukemia. Blood 100(8), 2703-2707 (2002).
101. Barragan E, Collado M, Cervera J et al. The GST deletions and NQO1*2 polymorphism confers interindividual variability of response to treatment in patients with acute myeloid leukemia. Leuk. Res. 31(7), 947-953 (2007). (Pubitemid 46856725)
102. Weiss JR, Kopecky KJ, Godwin J et al. Glutathione S-transferase (GSTM1, GSTT1 and GSTA1) polymorphisms and outcomes after treatment for acute myeloid leukemia: pharmacogenetics in Southwest Oncology Group (SWOG) clinical trials. Leukemia 20(12), 2169-2171 (2006). (Pubitemid 44782843)
103. Voso MT, Hohaus S, Guidi F et al. Prognostic role of glutathione S-transferase polymorphisms in acute myeloid leukemia. Leukemia 22(9), 1685-1691 (2008).
104. Karp JE, Lancet JE. Development of farnesyltransferase inhibitors for clinical cancer therapy: focus on hematologic malignancies. Cancer Invest. 25(6), 484-494 (2007). (Pubitemid 47450675)
105. Sousa SF, Fernandes PA, Ramos MJ. Farnesyltransferase inhibitors: a detailed chemical view on an elusive biological problem. Curr. Med. Chem. 15(15), 1478-1492 (2008). (Pubitemid 351997780)
106. Sebti SM, Adjei AA. Farnesyltransferase inhibitors. Semin. Oncol. 31(1 Suppl. 1), S28-S39 (2004).
107. Rowinsky EK, Windle JJ, Von Hoff DD. Ras protein farnesyltransferase: a strategic target for anticancer therapeutic development. J. Clin. Oncol. 17(11), 3631-3652 (1999). (Pubitemid 29517936)
108. Karp JE, Lancet JE, Kaufmann SH et al. Clinical and biologic activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: a Phase 1 clinical-laboratory correlative trial. Blood 97(11), 3361-3369 (2001).
109. Harousseau JL, Lancet JE, Reiffers J et al. A Phase 2 study of the oral farnesyltransferase inhibitor tipifarnib in patients with refractory or relapsed acute myeloid leukemia. Blood 109(12), 5151-5156 (2007). (Pubitemid 46890529)
110. Lancet JE, Gojo I, Gotlib J et al. A Phase 2 study of the farnesyltransferase inhibitor tipifarnib in poor-risk and elderly patients with previously untreated acute myelogenous leukemia. Blood 109(4), 1387-1394 (2007). (Pubitemid 46242109)
111. Harousseau JL, Martinelli G, Jedrzejczak WW et al. A randomized Phase 3 study of tipifarnib compared with best supportive care, including hydroxyurea, in the treatment of newly diagnosed acute myeloid leukemia in patients 70 years or older. Blood 114(6), 1166-1173 (2009).
112. Karp JE, Flatten K, Feldman EJ et al. Active oral regimen for elderly adults with newly diagnosed acute myelogenous leukemia: a preclinical and Phase 1 trial of the farnesyltransferase inhibitor tipifarnib (R115777, Zarnestra) combined with etoposide. Blood 113(20), 4841-4852 (2009).
113. Raponi M, Belly RT, Karp JE, Lancet JE, Atkins D, Wang Y. Microarray analysis reveals genetic pathways modulated by tipifarnib in acute myeloid leukemia. BMC Cancer 4, 56 (2004).
114. Raponi M, Harousseau JL, Lancet JE et al. Identification of molecular predictors of response in a study of tipifarnib treatment in relapsed and refractory acute myelogenous leukemia. Clin. Cancer Res. 13(7), 2254-2260 (2007). (Pubitemid 46649895)
115. Raponi M, Lancet JE, Fan H et al. A 2-gene classifier for predicting response to the farnesyltransferase inhibitor tipifarnib in acute myeloid leukemia. Blood 111(5), 2589-2596 (2008).
116. Kosco KA, Cerignoli F, Williams S, Abraham RT, Mustelin T. SKAP55 modulates T cell antigen receptor-induced activation of the Ras-Erk-AP1 pathway by binding RasGRP1. Mol. Immunol. 45(2), 510-522 (2008). (Pubitemid 47332631)
117. Roose JP, Mollenauer M, Ho M, Kurosaki T, Weiss A. Unusual interplay of two types of Ras activators, RasGRP and SOS, establishes sensitive and robust Ras activation in lymphocytes. Mol. Cell. Biol. 27(7), 2732-2745 (2007). (Pubitemid 46581361)
118. Ferrarini M, Squintani G, Cavallaro T, Ferrari S, Rizzuto N, Fabrizi GM. A novel mutation of aprataxin associated with ataxia ocular apraxia type 1: phenotypical and genotypical characterization. J. Neurol. Sci. 260(1-2), 219-224 (2007). (Pubitemid 47212231)
119. Karp JE, Vener TI, Raponi M et al. Multi-institutional Phase 2 clinical and pharmacogenomic trial of tipifarnib plus etoposide for elderly adults with newly diagnosed acute myelogenous leukemia. Blood 119(1), 55-63 (2012).
120. Basso AD, Kirschmeier P, Bishop WR. Lipid posttranslational modifications. Farnesyl transferase inhibitors. J. Lipid Res. 47(1), 15-31 (2006).
121. Caloca MJ, Zugaza JL, Bustelo XR. Exchange factors of the RasGRP family mediate Ras activation in the Golgi. J. Biol. Chem. 278(35), 33465-33473 (2003). (Pubitemid 37055801)
122. Wall AM, Rubnitz JE. Pharmacogenomic effects on therapy for acute lymphoblastic leukemia in children. Pharmacogenomics J. 3(3), 128-135 (2003). (Pubitemid 36850155)
123. Rocha JC, Cheng C, Liu W et al. Pharmacogenetics of outcome in children with acute lymphoblastic leukemia. Blood 105(12), 4752-4758 (2005). (Pubitemid 40807300)
124. Holleman A, Den Boer ML, De Menezes RX et al. The expression of 70 apoptosis genes in relation to lineage, genetic subtype, cellular drug resistance, and outcome in childhood acute lymphoblastic leukemia. Blood 107(2), 769-776 (2006). (Pubitemid 43076404)
125. Yang YL, Lin DT, Chang SK et al. Pharmacogenomic variations in treatment protocols for childhood acute lymphoblastic leukemia. Pediatr. Blood Cancer 54(2), 206-211 (2010).